Nishant (for Geoff Meacham)'s questions to Kymera Therapeutics Inc (KYMR) leadership • Q1 2024
Question
Nishant, on behalf of Geoff Meacham, asked if genetic links between certain IRF5 isoforms and lupus raised concerns that KT-579 could worsen the disease in some patients, and if the degrader was designed to target specific isoforms.
Answer
Senior Director of Immunology Veronica Campbell and President and CEO Nello Mainolfi addressed the question. Veronica Campbell explained that targeting specific isoforms is difficult and that KT-579 is designed to degrade all of them. They believe this is the superior approach because disease can be driven by mechanisms beyond the genetic variants. Nello Mainolfi added that targeting all isoforms allows them to treat the broadest possible patient population.